For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Twist Bioscience Corp (NASDAQ: TWST) closed at $33.84 down -3.48% from its previous closing price of $35.06. In other words, the price has decreased by -$3.48 from its previous closing price. On the day, 0.8 million shares were traded. TWST stock price reached its highest trading level at $34.9 during the session, while it also had its lowest trading level at $33.285.
Ratios:
For a deeper understanding of Twist Bioscience Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.33 and its Current Ratio is at 3.64. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In the most recent recommendation for this company, Stephens on November 04, 2025, initiated with a Overweight rating and assigned the stock a target price of $41. On December 13, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $60. On June 04, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $53.Guggenheim initiated its Buy rating on June 04, 2024, with a $53 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 22 ’25 when Green Paula sold 273 shares for $34.56 per share. The transaction valued at 9,434 led to the insider holds 166,639 shares of the business.
Cho Dennis sold 324 shares of TWST for $11,196 on Dec 22 ’25. The insider now owns 144,680 shares after completing the transaction at $34.56 per share. On Dec 22 ’25, another insider, Leproust Emily M., who serves as the Chief Executive Officer of the company, sold 1,605 shares for $34.56 each. As a result, the insider received 55,462 and left with 874,313 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TWST now has a Market Capitalization of 2069249152 and an Enterprise Value of 1927387136. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.49 while its Price-to-Book (P/B) ratio in mrq is 4.34. Its current Enterprise Value per Revenue stands at 5.118 whereas that against EBITDA is -16.862.
Stock Price History:
The Beta on a monthly basis for TWST is 2.19, which has changed by -0.28783262 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, TWST has reached a high of $55.33, while it has fallen to a 52-week low of $23.30. The 50-Day Moving Average of the stock is 8.92%, while the 200-Day Moving Average is calculated to be 3.59%.
Shares Statistics:
For the past three months, TWST has traded an average of 1.68M shares per day and 1255870 over the past ten days. A total of 60.63M shares are outstanding, with a floating share count of 58.32M. Insiders hold about 4.63% of the company’s shares, while institutions hold 116.85% stake in the company. Shares short for TWST as of 1764288000 were 12752433 with a Short Ratio of 7.61, compared to 1761868800 on 10548267. Therefore, it implies a Short% of Shares Outstanding of 12752433 and a Short% of Float of 23.49.
Earnings Estimates
A comprehensive evaluation of Twist Bioscience Corp (TWST) is underway, with the input of 1.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.47 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$1.76 and -$1.76 for the fiscal current year, implying an average EPS of -$1.76. EPS for the following year is -$1.06, with 9.0 analysts recommending between -$0.64 and -$1.54.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $100.32M this quarter.It ranges from a high estimate of $101M to a low estimate of $100M. As of. The current estimate, Twist Bioscience Corp’s year-ago sales were $88.71MFor the next quarter, 7 analysts are estimating revenue of $104.98M. There is a high estimate of $109.1M for the next quarter, whereas the lowest estimate is $103.85M.
A total of 8 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $432.9M, while the lowest revenue estimate was $429.4M, resulting in an average revenue estimate of $430.66M. In the same quarter a year ago, actual revenue was $376.57MBased on 7 analysts’ estimates, the company’s revenue will be $497.2M in the next fiscal year. The high estimate is $503.8M and the low estimate is $485.63M.
